Waldenstrom Macroglobulinemia
"Waldenstrom Macroglobulinemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Descriptor ID |
D008258
|
| MeSH Number(s) |
C04.557.595.925 C14.907.454.960 C15.378.147.780.925 C15.378.463.515.960 C15.604.515.925 C20.683.780.925
|
| Concept/Terms |
Waldenstrom Macroglobulinemia- Waldenstrom Macroglobulinemia
- Macroglobulinemia, Waldenstrom
- Lymphoma, Lymphoplasmacytoid
- Lymphomas, Lymphoplasmacytoid
- Lymphoplasmacytoid Lymphoma
- Lymphoplasmacytoid Lymphomas
- Macroglobulinemia
- Waldenstrom's Macroglobulinemia
- Macroglobulinemia, Waldenstrom's
- Waldenstroms Macroglobulinemia
- Waldenstrom's Macroglobulinaemia
- Macroglobulinaemia, Waldenstrom's
- Waldenstrom Macroglobulinaemia
- Waldenstroms Macroglobulinaemia
- Lymphoma, Lymphocytic, Plasmacytoid
- Primary Macroglobulinemia
- Macroglobulinemia, Primary
Familial Waldenstrom's Macroglobulinaemia- Familial Waldenstrom's Macroglobulinaemia
- Familial Waldenstrom Macroglobulinaemia
- Familial Waldenstroms Macroglobulinaemia
- Macroglobulinaemia, Familial Waldenstrom's
- Waldenstrom's Macroglobulinaemia, Familial
|
Below are MeSH descriptors whose meaning is more general than "Waldenstrom Macroglobulinemia".
Below are MeSH descriptors whose meaning is more specific than "Waldenstrom Macroglobulinemia".
This graph shows the total number of publications written about "Waldenstrom Macroglobulinemia" by people in this website by year, and whether "Waldenstrom Macroglobulinemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 1 | 6 |
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2001 | 4 | 0 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 9 | 2 | 11 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2014 | 7 | 1 | 8 |
| 2015 | 12 | 0 | 12 |
| 2016 | 20 | 1 | 21 |
| 2017 | 7 | 0 | 7 |
| 2018 | 24 | 0 | 24 |
| 2019 | 11 | 0 | 11 |
| 2020 | 15 | 0 | 15 |
| 2021 | 16 | 0 | 16 |
| 2022 | 6 | 0 | 6 |
| 2023 | 8 | 0 | 8 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Waldenstrom Macroglobulinemia" by people in Profiles.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 Apr 09; 8(7):1639-1650.
-
Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.
-
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr?m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20; 41(33):5099-5106.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Waldenstr?m Macroglobulinemia: A Myriad of Effective Treatment Options, but Still Work to be Done. Hematol Oncol Clin North Am. 2023 Aug; 37(4):xiii-xiv.
-
Novel Agents in Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2023 Aug; 37(4):751-760.
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na?ve patients. Semin Hematol. 2023 03; 60(2):73-79.
-
Dose reductions in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023 06; 201(5):897-904.
-
Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347.
-
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Glob Oncol. 2022 08; 8:e2100380.